AUPH Aurinia Pharmaceuticals
- 8.340
- -0.080-0.95%
- 8.350
- +0.010+0.12%
Aurinia Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Siemens Healthineers AG (OtherSEMHF)
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $10.85
Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9.4
Aurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A Potential
Aurinia Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Aurinia Pharmaceuticals, Maintains $10 Price Target
Aurinia Pharmaceuticals Price Target Maintained With a $10.00/Share by Cantor Fitzgerald
Aurinia Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200's Clinical and Financial Promise
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $8
Analysts Have Conflicting Sentiments on These Healthcare Companies: UniQure (QURE), Aurinia Pharmaceuticals (AUPH) and Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Aurinia Pharmaceuticals: Strong Q2 Sales and Market Penetration Back Buy Rating
RBC Capital Gives a Buy Rating to Aurinia Pharmaceuticals (AUPH)
No Data